Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer

Timothy Kottke, Luis Sanchez-Perez, Rosa Maria Diaz, Jill Thompson, Heung Chong, Kevin Harrington, Stuart K. Calderwood, Jose Pulido, Nick Georgopoulos, Peter Selby, Alan Melcher, Richard Vile

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

A close connectivity between autoimmune and tumor rejection responses is known to exist in the case of melanoma immunotherapy. However, relatively little is known about self-antigens on other types of normal cells, their relation to the development of autoimmune disease, and their possible coexistence as potential tumor rejection antigens on associated tumors. In the current study, we induced inflammatory killing of normal prostate tissue in situ using a fusogenic membrane glycoprotein along with the immune adjuvant hsp70. We show here that, in the prostate, hsp70 induces interleukin (IL)-6, which triggers a CD4- and CD8-dependent progressive autoimmune reactivity, associated with IL-17 expression. This autoimmune response was also able to induce the rejection of established prostate tumors, but not other histologic types of tumors, growing elsewhere in the animal. These data show that the intimate connectivity between autoimmune and tumor rejection responses extends beyond the classic melanoma paradigm and may be clinically valuable for the treatment of established metastatic disease of the prostate.

Original languageEnglish
Pages (from-to)11970-11979
Number of pages10
JournalCancer Research
Volume67
Issue number24
DOIs
Publication statusPublished - 15 Dec 2007
Externally publishedYes

Fingerprint

Autoimmunity
Immunotherapy
Prostatic Neoplasms
Prostate
Neoplasms
Melanoma
Interleukin-17
Membrane Glycoproteins
Autoantigens
Neoplasm Antigens
Autoimmune Diseases
Interleukin-6
Therapeutics

Cite this

Kottke, T., Sanchez-Perez, L., Diaz, R. M., Thompson, J., Chong, H., Harrington, K., ... Vile, R. (2007). Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. Cancer Research, 67(24), 11970-11979. https://doi.org/10.1158/0008-5472.CAN-07-2259
Kottke, Timothy ; Sanchez-Perez, Luis ; Diaz, Rosa Maria ; Thompson, Jill ; Chong, Heung ; Harrington, Kevin ; Calderwood, Stuart K. ; Pulido, Jose ; Georgopoulos, Nick ; Selby, Peter ; Melcher, Alan ; Vile, Richard. / Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. In: Cancer Research. 2007 ; Vol. 67, No. 24. pp. 11970-11979.
@article{a9523f1635424f9c8b6348a4577a92cc,
title = "Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer",
abstract = "A close connectivity between autoimmune and tumor rejection responses is known to exist in the case of melanoma immunotherapy. However, relatively little is known about self-antigens on other types of normal cells, their relation to the development of autoimmune disease, and their possible coexistence as potential tumor rejection antigens on associated tumors. In the current study, we induced inflammatory killing of normal prostate tissue in situ using a fusogenic membrane glycoprotein along with the immune adjuvant hsp70. We show here that, in the prostate, hsp70 induces interleukin (IL)-6, which triggers a CD4- and CD8-dependent progressive autoimmune reactivity, associated with IL-17 expression. This autoimmune response was also able to induce the rejection of established prostate tumors, but not other histologic types of tumors, growing elsewhere in the animal. These data show that the intimate connectivity between autoimmune and tumor rejection responses extends beyond the classic melanoma paradigm and may be clinically valuable for the treatment of established metastatic disease of the prostate.",
keywords = "autoantigen, CD4 antigen, CD8 antigen, heat shock protein 70, interleukin 17, interleukin 6, membrane protein, cancer immunotherapy, prostate cancer",
author = "Timothy Kottke and Luis Sanchez-Perez and Diaz, {Rosa Maria} and Jill Thompson and Heung Chong and Kevin Harrington and Calderwood, {Stuart K.} and Jose Pulido and Nick Georgopoulos and Peter Selby and Alan Melcher and Richard Vile",
year = "2007",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-07-2259",
language = "English",
volume = "67",
pages = "11970--11979",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

Kottke, T, Sanchez-Perez, L, Diaz, RM, Thompson, J, Chong, H, Harrington, K, Calderwood, SK, Pulido, J, Georgopoulos, N, Selby, P, Melcher, A & Vile, R 2007, 'Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer', Cancer Research, vol. 67, no. 24, pp. 11970-11979. https://doi.org/10.1158/0008-5472.CAN-07-2259

Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. / Kottke, Timothy; Sanchez-Perez, Luis; Diaz, Rosa Maria; Thompson, Jill; Chong, Heung; Harrington, Kevin; Calderwood, Stuart K.; Pulido, Jose; Georgopoulos, Nick; Selby, Peter; Melcher, Alan; Vile, Richard.

In: Cancer Research, Vol. 67, No. 24, 15.12.2007, p. 11970-11979.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Induction of hsp70-mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer

AU - Kottke, Timothy

AU - Sanchez-Perez, Luis

AU - Diaz, Rosa Maria

AU - Thompson, Jill

AU - Chong, Heung

AU - Harrington, Kevin

AU - Calderwood, Stuart K.

AU - Pulido, Jose

AU - Georgopoulos, Nick

AU - Selby, Peter

AU - Melcher, Alan

AU - Vile, Richard

PY - 2007/12/15

Y1 - 2007/12/15

N2 - A close connectivity between autoimmune and tumor rejection responses is known to exist in the case of melanoma immunotherapy. However, relatively little is known about self-antigens on other types of normal cells, their relation to the development of autoimmune disease, and their possible coexistence as potential tumor rejection antigens on associated tumors. In the current study, we induced inflammatory killing of normal prostate tissue in situ using a fusogenic membrane glycoprotein along with the immune adjuvant hsp70. We show here that, in the prostate, hsp70 induces interleukin (IL)-6, which triggers a CD4- and CD8-dependent progressive autoimmune reactivity, associated with IL-17 expression. This autoimmune response was also able to induce the rejection of established prostate tumors, but not other histologic types of tumors, growing elsewhere in the animal. These data show that the intimate connectivity between autoimmune and tumor rejection responses extends beyond the classic melanoma paradigm and may be clinically valuable for the treatment of established metastatic disease of the prostate.

AB - A close connectivity between autoimmune and tumor rejection responses is known to exist in the case of melanoma immunotherapy. However, relatively little is known about self-antigens on other types of normal cells, their relation to the development of autoimmune disease, and their possible coexistence as potential tumor rejection antigens on associated tumors. In the current study, we induced inflammatory killing of normal prostate tissue in situ using a fusogenic membrane glycoprotein along with the immune adjuvant hsp70. We show here that, in the prostate, hsp70 induces interleukin (IL)-6, which triggers a CD4- and CD8-dependent progressive autoimmune reactivity, associated with IL-17 expression. This autoimmune response was also able to induce the rejection of established prostate tumors, but not other histologic types of tumors, growing elsewhere in the animal. These data show that the intimate connectivity between autoimmune and tumor rejection responses extends beyond the classic melanoma paradigm and may be clinically valuable for the treatment of established metastatic disease of the prostate.

KW - autoantigen

KW - CD4 antigen

KW - CD8 antigen

KW - heat shock protein 70

KW - interleukin 17

KW - interleukin 6

KW - membrane protein

KW - cancer immunotherapy

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=37549008775&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-2259

DO - 10.1158/0008-5472.CAN-07-2259

M3 - Article

C2 - 18089828

AN - SCOPUS:37549008775

VL - 67

SP - 11970

EP - 11979

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -